$MLYS insider trading

Over the last 12 months, Mineralys Therapeutics insiders reported no purchases and 10 sales totaling $6.4M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.

$6.4M
10
4
100%
Side
$10K$100K$1.0M$10MJun '26JulAug
Rodman David Malcom
Congleton Jon
Warren Eric
Karydas Daphne

All insider trades

Jul 21, 2026Warren Eric▼ Sale7,438$26.87$200K-16.2%
Jul 17, 2026Rodman David Malcom▼ Sale416$26.53$11K-0.8%
Jul 15, 2026Rodman David Malcom▼ Sale20,407$27.28$557K-28.4%
Jul 13, 2026Congleton Jon▼ Sale10,700$27.24$291K-1.7%
Jul 9, 2026Rodman David Malcom▼ Sale2,171$30.3$66K-3.6%
Jun 30, 2026Congleton Jon▼ Sale75,000$26.14$2.0M-10.9%
Jun 26, 2026Warren Eric▼ Sale104,124$25.9$2.7M-73.1%
Jun 17, 2026Rodman David Malcom▼ Sale14,474$24.19$350K-20.2%
Jun 17, 2026Karydas Daphne▼ Sale3,000$25$75K-32.6%
Jun 12, 2026Rodman David Malcom▼ Sale8,519$24.2$206K-11.8%

Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $MLYS feed.

MLYS Insider Trading — Form 4 Buys & Sells | alphai